Adage Capital Partners
ATRA icon

Adage Capital Partners’s Atara Biotherapeutics ATRA Stock Holding History

Adage Capital Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.76M Buy
850,000
+150,000
+21% +$1.2M 0.01% 729
2026
Q1 		$3.31M Buy
+700,000
New +$4.27M 0.01% 806
2017
Q2 		– Sell
-7,160
Closed -$3.68M – 704
2017
Q1 		$3.68M Hold
7,160
– – 0.01% 636
2016
Q4 		$2.54M Buy
+7,160
New +$3.03M 0.01% 644

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Adage Capital Partners's ATRA Position: Q2 2026 in Review

Adage Capital Partners increased its Atara Biotherapeutics (ATRA) stake by 21% in Q2 2026, buying an estimated $1.2M and bringing the position to 850,000 shares worth $9.76M. The position accounts for 0.01% of the portfolio, ranked #729.

Adage Capital Partners first reported a position in ATRA in Q4 2016 and has held it in 4 quarters since. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Adage Capital Partners held 850,000 shares of Atara Biotherapeutics worth $9.76M as of Q2 2026.
  • Adage Capital Partners bought 150,000 Atara Biotherapeutics shares in Q2 2026, an estimated $1.2M.
  • Atara Biotherapeutics made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #729 holding.
  • Adage Capital Partners first reported a position in Atara Biotherapeutics in Q4 2016 and has held it in 4 quarters since.
  • 36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.